Merit Medical Q1 adjusted EPS rises on therapeutic, foundational growth

Merit Medical Systems

30/04/2026 21:58

Overview

U.S. medical device maker's Q1 revenue rose 7% yr/yr

Adjusted EPS for Q1 beat analyst expectations

Company divested DualCap product line and acquired View Point Medical to expand oncology offerings

Outlook

Merit expects 2026 revenue of $1.612-$1.634 bln, up 6%-8% from prior yr

Company sees 2026 non-GAAP EPS of $4.01-$4.15, up 5%-8% from prior yr

Acquisition of View Point Medical expected to add $2-$4 mln to 2026 revenue, dilute non-GAAP EPS by $0.05

Result Drivers

PRODUCT CATEGORY GROWTH - Revenue grew in both Foundational and Therapeutic categories, with Therapeutic up 10% and Foundational up 6% yr/yr

DIVESTITURE IMPACT - Organic, constant currency revenue growth was 3.7% excluding the impact of the DualCap product line divestiture

MARGIN IMPROVEMENT - Non-GAAP operating margin increased to 19.7% from 19.3% despite incremental year-over-year headwinds from tariffs

Company press release: ID:nGNX8yxY9p

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Adjusted EPS
Beat
$0.94
$0.83 (10 Analysts)
Q1 EPS
$0.68
Q1 Adjusted Net Income
Beat
$56.70 mln
$48.77 mln (10 Analysts)

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

Wall Street's median 12-month price target for Merit Medical Systems Inc is $98.00, about 51.1% above its April 29 closing price of $64.84

The stock recently traded at 16 times the next 12-month earnings vs. a P/E of 22 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)